BRPI0606143A2 - terapia de combinação - Google Patents

terapia de combinação

Info

Publication number
BRPI0606143A2
BRPI0606143A2 BRPI0606143-5A BRPI0606143A BRPI0606143A2 BR PI0606143 A2 BRPI0606143 A2 BR PI0606143A2 BR PI0606143 A BRPI0606143 A BR PI0606143A BR PI0606143 A2 BRPI0606143 A2 BR PI0606143A2
Authority
BR
Brazil
Prior art keywords
combination therapy
combination
drug
scd
inhibitors
Prior art date
Application number
BRPI0606143-5A
Other languages
English (en)
Inventor
Rajender Kamboj
Michael Winther
Robert Fraser
Mikhail Chafeev
Sultan Chowdhury
Jian-Min Fu
Duanjie Hou
Shifeng Liu
Vandna Raina
Mehran Seid Bagherzadeh
Serguei Sviridov
Kashinath Sadalapure
Shaoyi Sun
Vishnumurthy Kodumuru
Nagasree Chakka
Zaihui Zhang
Melwyn Abreo
Mikhail A Kondratenko
Daniel F Harvey
Cindy J Hudson
Wenbao Li
Chi Tu
Sengen Sun
Mark W Holladay
Heinz W Gschwend
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of BRPI0606143A2 publication Critical patent/BRPI0606143A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

TERAPIA DE COMBINAçãO. Esta invenção está direcionada ao uso de inibidores de SCD-1 da Fórmula (I): onde x, y, V, W, G, J, L, M, R^ 2^, R^ 3^, R^ 5^, R^ 5a^, R^ 6^, R^ 6a^, R^ 7^, R^ 7a^, R^ 8^ e R^ 8a^ são de- finidos aqui, em combinação com outras terapias de fármaco para tratar o ganho de peso adverso.
BRPI0606143-5A 2005-02-09 2006-02-08 terapia de combinação BRPI0606143A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65158405P 2005-02-09 2005-02-09
PCT/US2006/004383 WO2006086445A2 (en) 2005-02-09 2006-02-08 Combination therapy

Publications (1)

Publication Number Publication Date
BRPI0606143A2 true BRPI0606143A2 (pt) 2009-06-02

Family

ID=36603292

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606143-5A BRPI0606143A2 (pt) 2005-02-09 2006-02-08 terapia de combinação

Country Status (13)

Country Link
US (1) US7919484B2 (pt)
EP (1) EP1846035B1 (pt)
JP (1) JP2008530097A (pt)
CN (1) CN101163504A (pt)
AR (1) AR053331A1 (pt)
AT (1) ATE525088T1 (pt)
AU (1) AU2006212761B2 (pt)
BR (1) BRPI0606143A2 (pt)
CA (1) CA2597067A1 (pt)
GT (1) GT200600046A (pt)
MX (1) MX2007009592A (pt)
TW (1) TW200638945A (pt)
WO (1) WO2006086445A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261250B2 (en) * 2003-07-29 2009-02-26 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
JP2009501733A (ja) * 2005-07-20 2009-01-22 メルク フロスト カナダ リミテツド ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのヘテロ芳香族化合物
AU2006326815A1 (en) 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
JP5432716B2 (ja) 2006-10-17 2014-03-05 ヌーボ リサーチ インコーポレイテッド ジクロフェナクゲル
TW200826936A (en) 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
US8575167B2 (en) 2007-02-06 2013-11-05 Takeda Pharmaceutical Company Limited Spiro compounds having stearoyl-CoA desaturase action
PL2142529T3 (pl) * 2007-04-27 2014-06-30 Purdue Pharma Lp Antagoniści trpv1 i ich zastosowania
AR066911A1 (es) 2007-06-08 2009-09-23 Janssen Pharmaceutica Nv Derivados de piperidina / piperazina
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
JP5443342B2 (ja) 2007-06-08 2014-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン／ピペラジン誘導体
WO2008148851A1 (en) * 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
WO2008157844A1 (en) 2007-06-21 2008-12-24 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
JP5579170B2 (ja) 2008-06-05 2014-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｄｇａｔ阻害剤とｐｐａｒ作動薬を含有する薬剤組み合わせ物
EP2328898B1 (de) 2008-09-09 2014-12-24 Sanofi 2-heteroaryl-pyrrolo[3,4-c]pyrrol- derivate und ihre verwendung als scd inhibitoren
AU2009304508A1 (en) * 2008-10-17 2010-04-22 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
MX2011008562A (es) * 2009-02-12 2011-09-09 Proyecto Biomedicina Cima Sl Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabolicas.
WO2010094120A1 (en) 2009-02-17 2010-08-26 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US8546450B1 (en) 2009-03-31 2013-10-01 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
GB0907425D0 (en) * 2009-04-29 2009-06-10 Glaxo Group Ltd Compounds
WO2011011872A1 (en) 2009-07-28 2011-02-03 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US20110101885A1 (en) * 2009-11-02 2011-05-05 Eric Yang Led backlight circuit for lcd panels
US9492422B2 (en) 2009-11-13 2016-11-15 Toray Industries, Inc. Therapeutic or prophylactic agent for diabetes
WO2012173952A1 (en) * 2011-06-13 2012-12-20 Emory University Piperazine derivatives, compositions, and uses related thereto
RU2621708C2 (ru) 2011-06-22 2017-06-07 ПУРДЬЮ ФАРМА Эл. Пи. Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение
WO2013175474A2 (en) 2012-05-22 2013-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Selective inhibitors of undifferentiated cells
WO2018081167A1 (en) 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
EP3566055A4 (en) 2017-01-06 2020-12-02 Yumanity Therapeutics, Inc. TREATMENT METHODS FOR NEUROLOGICAL DISORDERS
MX2018014032A (es) 2017-03-20 2019-08-21 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato cinasa (pkr).
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614238D0 (en) * 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
AU4414999A (en) * 1998-06-08 1999-12-30 Sambasiva R. Chavali Inhibition of delta-9-desaturase activity by saponins
US20030064950A1 (en) * 2001-02-23 2003-04-03 Ntambi James M. Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity
EP1388352A1 (en) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
AU2003294446A1 (en) 2002-11-21 2004-06-18 Bayer Pharmaceuticals Corporation Regulation of stearoyl-coa desaturase to treat obesity
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20060258683A1 (en) * 2003-04-07 2006-11-16 Liu Kevin Para-sulfonyl substituted phenyl compounds as modulators of ppars
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
US7335658B2 (en) * 2003-07-30 2008-02-26 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
CA2580787A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes

Also Published As

Publication number Publication date
JP2008530097A (ja) 2008-08-07
WO2006086445A3 (en) 2006-09-14
EP1846035B1 (en) 2011-09-21
AU2006212761B2 (en) 2009-07-02
WO2006086445A8 (en) 2006-12-07
WO2006086445A2 (en) 2006-08-17
AR053331A1 (es) 2007-05-02
ATE525088T1 (de) 2011-10-15
MX2007009592A (es) 2007-10-16
EP1846035A2 (en) 2007-10-24
GT200600046A (es) 2006-09-25
US20090131447A1 (en) 2009-05-21
CA2597067A1 (en) 2006-08-17
CN101163504A (zh) 2008-04-16
AU2006212761A1 (en) 2006-08-17
TW200638945A (en) 2006-11-16
US7919484B2 (en) 2011-04-05

Similar Documents

Publication Publication Date Title
BRPI0606143A2 (pt) terapia de combinação
CY1115188T1 (el) Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
BRPI0517015A (pt) compostos e composições como inibidores de atividade de receptor 1 de canabinóide
ATE520668T1 (de) Sigmarezeptor-inhibitoren
CY1112206T1 (el) Παραγωγα πυριδαζινονης για την θεραπεια ογκων
ECSP088503A (es) COMPUESTOS de LACTAMa y MÉTODOS DE USO DE LOS MISMOS
DE602004013563D1 (de) Rantagonisten
NO20082414L (no) Inhibitorer av AKT-aktivitet
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
BRPI0514444A (pt) análogos de ciclopamina e métodos de uso destes
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
BR0314235A (pt) Compostos de fenil-aza-benzimidazol para modulação de ige e inibição da proliferação celular
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
MXJL03000027A (es) Compuestos de benzimidazol para modular la ige e inhibir la proliferacion celular.
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
ATE368657T1 (de) Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
EA200800014A1 (ru) Аминохинолиновые и аминохиназолиновые модуляторы киназы
TW200630367A (en) Substituted adenines and the uses thereof
UA99434C2 (ru) Применение производных алкилфосфолипидов со сниженной цитотоксичностью
ATE434614T1 (de) 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer
CL2008002954A1 (es) Compuestos derivados de 1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahidrociclopenta-(5,6)nafto-(1,2-f)indazol heterociclo o carbociclo sustituido; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de asma, epoc, rinits alergica.
MX2008001538A (es) Aril piridinas y metodos para su uso.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.